<DOC>
	<DOCNO>NCT01561053</DOCNO>
	<brief_summary>The purpose study evaluate change cognitive , functional , behavioral global domain base different applicable psychometric battery scale .</brief_summary>
	<brief_title>A Study Evaluate Albumin Immunoglobulin Alzheimer 's Disease</brief_title>
	<detailed_description>A clinical trial comprise 350 subject probable mild moderate Alzheimer 's Disease ( AD ) conduct primarily determine whether plasmapheresis infusion human albumin combine Intravenous immunoglobulin ( IVIG ) able modify patient 's cognitive , functional , behavioral global domain . There 3 treatment group one control group . The subject randomize 1:1:1:1 proportion .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Main 1 . Males females 5585 year age time sign informed consent document . 2 . A diagnosis Alzheimer 's disease ( NINCDSADRDA criterion ) , MMSE score &gt; /=18 &lt; /=26 . 3 . Current stable treatment AChEIs and/or memantine previous three month . 4 . The patient close relative legal representative must read patient information sheet , agree participation trial , sign inform consent document ( patient personally close relative/legal representative ) . 5 . The patient must able follow study protocol , receive treatment establish time period , continue followup interval . 6 . A brain CAT MRI study obtain 12 month prior recruitment , show absence cerebrovascular disease , available . Nevertheless , possible use MRI obtain screen period rule cerebral vascular disease . 7 . A stable care taker must available , must attend patient study visit . Main 1 . Any contraindication plasma exchange due behavioral disorder abnormal coagulation parameter , example : Hypocalcemia ( Ca++ &lt; 8.7 mg/dL ) Thrombocytopenia ( &lt; 100,000/µL ) Fibrinogen &lt; 1.5 g/L ) Prothrombin time ( Quick ) p &lt; 60 % versus control ( INR &gt; 1.5 ) Betablocker treatment bradycardia &lt; 60/min ) Treatment angiotensionconverting enzyme inhibitor ( ACEIs ) ( increase risk allergic reaction ) 2 . Hemoglobin &lt; 10 mg/dL 3 . Difficult venous access preclude plasma exchange . 4 . A history frequent adverse reaction ( serious otherwise ) blood product . 5 . Hypersensitivity albumin allergy component Albutein® 5 % . 6 . History immunoglobulin A ( IgA ) deficiency . 7 . Known allergy Flebogamma® DIF component sorbitol . 8 . History thromboembolic complication intravenous immunoglobulin . 9 . Plasma creatinine &gt; 2 mg/dl . 10 . Uncontrolled high blood pressure ( systolic blood pressure 160 mmHg high and/or diastolic blood pressure 100 mmHg high despite treatment last 3 month ) . 11 . Liver cirrhosis liver problem GPT &gt; 2.5 x ULN , bilirubin &gt; 2 mg/dL . 12 . Heart diseases , evidence myocardial infarction , severe unstable angina , heart failure ( New York Association Class II , III IV ) past 12 month . 13 . Participation clinical trial , receiption investigational drug three month prior start study . 14 . Any condition complicate adherence study protocol ( illness less one year expect survival , know drug alcohol abuse , etc. ) . 15 . Pregnant nursing woman woman use effective contraceptive method least one month plasma exchange . 16 . Fewer six year education ( exclusion criterion medical criterion ) . 17 . Fewer three month stable treatment behavioral disorder insomnia .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>AB peptide</keyword>
	<keyword>Albumin</keyword>
	<keyword>Intravenous immune globulin</keyword>
	<keyword>IGIV</keyword>
</DOC>